Trial to test combination of Sputnik V and COVID-19 Vaccine AstraZeneca

9 February 2021

Approval has been granted by the Azerbaijani authorities for a trial to proceed testing the combined use of the Sputnik V vaccine and AstraZeneca’s (LSE: AZN) jab to protect against COVID-19.

Previously, Moscow’s Gamaleya National Center, where Sputnik V was developed, along with the Russian Direct Investment Fund (RDIF), AstraZeneca and R-Pharm, signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020 in the presence of President Vladimir Putin.

"We need to join our international efforts and use the most advanced solutions to defeat the coronavirus"The research aims to evaluate the immunogenicity and safety of the Sputnik V and AstraZeneca vaccines in combined use. The research program will take place in several countries, enrolling 100 adults aged 18 years and older.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK